(800) 429-3205

Submit Your Information for the Scynexis Lawsuit

Lead plaintiff deadline is January 8, 2024.

If you purchased or acquired Scynexis securities between March 31, 2023 and September 22, 2023, please contact Berger Montague using the form below.

Please view our terms of use policy and our privacy policy.

First Name *

Last Name *

Email *

Phone Number *

Address

City

Zip

State

Are you a current or former employee of Scynexis?

How many shares did you purchase? Please provide ALL transactions.

What dates did you purchase? Please provide ALL dates.

What was the price per share when you purchased? Please provide ALL prices.

I agree to the terms of service

I would like to receive updates from Berger Montague

Thank you! Your form has been successfully submitted.

About the Case

The lawsuit alleges that the truth regarding Scynexis emerged on September 25, 2023, when Scynexis announced that it “became aware that a non-antibacterial beta-lactam drug substance is manufactured using equipment common to the manufacturing process for ibrexafungerp.” As a result, Scynexis recalled BREXAFEMME® (ibrexafungerp tablets) from the market and put a temporary hold in ibrexafungerp clinical studies “until a mitigation strategy and a resupply plan are determined.”

Following this news, Scynexis’s shares fell $1.13, or 34.14%, to close at $2.18 per share on September 25, 2023. The stock price continued to fall the next trading session by 11.47%, to close at $1.93 per share on September 26, 2023.

Investors who purchased or acquired Scynexis securities between March 31, 2023 and September 22, 2023, may no later than January 8, 2024, seek to be appointed as a lead plaintiff representative of the class.